What's Happening?
Adcendo ApS, a biotechnology company, has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc.) to evaluate the combination of ADCE-T02 and KEYTRUDA® (pembrolizumab) in a Phase Ib study. ADCE-T02 is an antibody-drug
conjugate (ADC) targeting Tissue Factor, a protein overexpressed in various solid tumors. The study aims to assess the safety, tolerability, and preliminary efficacy of this combination in patients with advanced solid tumors. Adcendo will sponsor the trial, while MSD will supply pembrolizumab. This collaboration seeks to leverage the complementary mechanisms of the two therapies to enhance anti-tumor activity.
Why It's Important?
This collaboration between Adcendo and MSD is significant as it explores a novel therapeutic approach for treating advanced solid tumors, which often have limited treatment options. By combining ADCE-T02 with pembrolizumab, the study aims to improve clinical outcomes for patients with cancers where Tissue Factor is overexpressed, such as head and neck squamous cell carcinoma and non-small cell lung cancer. The success of this trial could lead to new treatment paradigms and expand the use of ADCs in oncology. Additionally, it highlights the potential of strategic partnerships in advancing cancer therapies and addressing unmet medical needs.
What's Next?
Adcendo plans to begin dosing patients in the Phase Ib study in the second half of 2026. The trial will investigate escalating doses of ADCE-T02 in combination with pembrolizumab to determine the optimal therapeutic regimen. If successful, this study could pave the way for further clinical development and potential regulatory approval of the combination therapy. The collaboration may also encourage additional research into ADCs and their integration with existing cancer treatments, potentially leading to more effective and personalized therapeutic options for patients with advanced solid tumors.
